DDInter1628 DDInter1891
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tucatinib
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Weight increased
Weight increased {u} (Side Effect) is caused by {v} (Compound) Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tucatinib
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Quinine
Quinine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Weight increased
Weight increased {u} (Side Effect) is caused by {v} (Compound) Letrozole
Letrozole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Hypercholesterolaemia
Hypercholesterolaemia {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Tucatinib
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tucatinib
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Prednisolone
Prednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Ruxolitinib {u} (Compound) upregulates {v} (Gene) CNOT4
CNOT4 {u} (Gene) is upregulated by {v} (Compound) Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Ruxolitinib {u} (Compound) upregulates {v} (Gene) RPP38
RPP38 {u} (Gene) is downregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Ruxolitinib {u} (Compound) downregulates {v} (Gene) NPDC1
NPDC1 {u} (Gene) is downregulated by {v} (Compound) Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Ruxolitinib (Compound) causes Weight increased (Side Effect) and Weight increased (Side Effect) is caused by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Quinine (Compound) and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Ruxolitinib (Compound) causes Weight increased (Side Effect) and Weight increased (Side Effect) is caused by Letrozole (Compound) and Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Ruxolitinib (Compound) causes Hypercholesterolaemia (Side Effect) and Hypercholesterolaemia (Side Effect) is caused by Nilotinib (Compound) and Nilotinib may lead to a major life threatening interaction when taken with Tucatinib
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Bexarotene (Compound) and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Ruxolitinib (Compound) upregulates CNOT4 (Gene) and CNOT4 (Gene) is upregulated by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Ruxolitinib (Compound) upregulates RPP38 (Gene) and RPP38 (Gene) is downregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Ruxolitinib (Compound) downregulates NPDC1 (Gene) and NPDC1 (Gene) is downregulated by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib